Compare BioNano Genomics Inc (BNGO) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs QUALCOMM, Inc. — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while QUALCOMM, Inc. trades at $163.23 (market cap $170.81B). The key difference: QUALCOMM, Inc. is far larger — about 12504.4× BioNano Genomics Inc's market cap, and QUALCOMM, Inc. pays a 2.26% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | QCOM | |
|---|---|---|
Market Cap | $13.66M | $170.81B |
Sector | Health | Technology |
52-Week High | $4.92 | $251.10 |
52-Week Low | $1.06 | $124.07 |
Enterprise Value | $16.26M | $177.78B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Qualcomm (QCOM) trades at $162.17, down 3.39% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong revenue of $44.28B in 2025 but saw net income decline to $5.54B, reflecting margin pressures. Recent news highlights Qualcomm's AI and data center expansion efforts, including the 'Dragonfly' AI platform announcement at COMPUTEX 2026, while facing increased competition from Nvidia in the PC chip market.
The outlook remains balanced with a consensus price target of $200.56 suggesting 24% upside, but near-term headwinds include smartphone market softness and margin compression. Long-term growth drivers in automotive and AI inference markets provide opportunity, though execution risks and competitive threats from chip rivals pose challenges for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
